



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Galvin, Katherine *et al.*

Serial No.: 09/635,521

Filed: August 9, 2000

For: METHODS AND COMPOSITIONS FOR THE
DIAGNOSIS AND TREATMENT OF
CARDIOVASCULAR AND TUMORIGENIC
DISEASE USING 4941

Attorney Docket No.: MNI-094

Group Art Unit: 1636

Examiner: Loeb, Bronwen

RECEIVED

AUG 14 2002

TECH CENTER 1600/2000

Commissioner for Patents
Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

August 6, 2002

Date of Signature and of Mail Deposit

By:


Maria C. Laccotripe, Ph.D.

Attorney for Applicants

Limited Recognition Under 37 CFR §10.9(b)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed June 24, 2002 during the prosecution of PCT/US01/13788 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's


consideration. These publications are cited on the enclosed PTO Form 1449, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(e)(1), the undersigned hereby certifies that each item contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application *for the first time* not more than three months prior to the filing of this statement.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Maria C. Laccotripe, Ph.D.
Attorney for Applicants
Limited Recognition Under 37 CFR§10.9(b)

28 State Street
Boston, MA 02109
(617) 227-7400

Date: August 6, 2002

GAD/AEM/MCL/JXS/ham
Enclosures